Form 4: Edwards Lifesciences Executive Equity Grant Disclosure

Edwards Lifesciences CVP Daveen Chopra received equity-based compensation including stock options and restricted stock units.

Summary

• Daveen Chopra, CVP of TMTT & Surgical, was granted 9,675 restricted stock units (RSUs) and 49,100 employee stock options on May 7, 2026.
• The RSUs vest in four equal annual installments starting one year after the grant date.
• The employee stock options have an exercise price of $82.76 and vest in four equal annual installments starting May 7, 2027.
• A portion of the shares (1,815 total) were withheld by the company to cover tax obligations related to the vesting of equity awards.
• Performance-based restricted stock units were also granted, with vesting contingent on performance goals over a three-year period.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine regulatory disclosure regarding executive compensation, which is neutral in terms of immediate market impact.

Positives

• Equity grants align executive interests with long-term shareholder value creation.
• Performance-based vesting criteria for a portion of the awards incentivize achievement of strategic goals.

Negatives

• The issuance of new equity awards results in potential dilution for existing shareholders.

Risks

• Vesting of performance-based units is subject to the achievement of specific goals, which may not be met.
• Market price volatility could impact the ultimate value of the granted options and RSUs.

Future Outlook

The executive's compensation is tied to long-term performance, with vesting schedules extending through 2029 and options exercisable through 2033, indicating a focus on multi-year corporate growth.

Management Comments

• The grants were issued under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program.

Industry Context

StockSavvy.ai notes that equity-based compensation for senior leadership in the medical device sector is standard practice to retain talent and ensure alignment with long-term R&D and commercialization milestones.

Comparison to Industry Standards

• The use of a mix of time-based RSUs and performance-based equity is consistent with compensation structures at peer companies like Medtronic and Boston Scientific.
• Four-year vesting schedules are standard practice for executive equity retention in the healthcare industry.

Stakeholder Impact

• Shareholders may experience minor dilution from the issuance of new equity.
• The executive is incentivized to drive long-term performance, which aligns with shareholder interests.

Next Steps

• Vesting of initial equity tranches on May 7, 2027.
• Performance evaluation for performance-based units concluding in 2029.

Key Dates

Keywords

Edwards Lifesciences, EW, Form 4, Insider Trading, Executive Compensation, Equity Incentive Plan